Millennium Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Millennium Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$727K	–	6389
2025 Q2	$727K	Buy	+20,000	New	+$721K	﹤0.01%	4647
2024 Q2	–	Sell	-200,300	Closed	-$9.35M	–	6413
2024 Q1	$9.35M	Buy	+200,300	New	+$9.45M	﹤0.01%	2251
2023 Q3	–	Sell	-15,000	Closed	-$692K	–	6479
2023 Q2	$692K	Buy	+15,000	New	+$696K	﹤0.01%	4315
2021 Q2	–	Sell	-65,000	Closed	-$7.4M	–	6999
2021 Q1	$7.4M	Buy	65,000 +57,700	+790%	+$7.86M	0.01%	2129
2020 Q4	$1.01M	Buy	+7,300	New	+$866K	﹤0.01%	3733

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Millennium Management's RARE Position: Q1 2026 in Review

Millennium Management increased its Ultragenyx Pharmaceutical (RARE) stake by 101% in Q1 2026, buying an estimated $20.1M and bringing the position to 1,772,184 shares worth $37.1M. The position accounts for 0.02% of the portfolio, ranked #1060.

Millennium Management first reported a position in RARE in Q1 2014 and has held it in 41 quarters since. The position peaked at $76.1M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Millennium Management held 1,772,184 shares of Ultragenyx Pharmaceutical worth $37.1M as of Q1 2026.
Millennium Management bought 891,540 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $20.1M.
Ultragenyx Pharmaceutical made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1060 holding.
Millennium Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 41 quarters since.
Millennium Management's Ultragenyx Pharmaceutical position peaked at $76.1M in Q2 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.